Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 24, 2024 09:15 ET | Source: Research and Markets

U.S. Non-alcoholic Steatohepatitis Biomarkers (Serum, Hepatic Fibrosis, Apoptosis) Market Research 2024-2030: Increasing Prevalence of Obesity, Type 2 Diabetes, and Metabolic Syndrome Fueling Demand

Dublin, July 24, 2024 (GLOBE NEWSWIRE) -- The "U.S. Non-alcoholic Steatohepatitis Biomarkers Market Size, Share & Trends Analysis Report by Type (Serum, Hepatic Fibrosis, Apoptosis), End-use...
April 30, 2024 09:00 ET | Source: Nacuity Pharmaceuticals, Inc.

Nacuity Pharmaceuticals Announces First Patients Implanted in Final Cohort of Phase 1/2 Clinical Trial Evaluating NPI-002 Intravitreal Implant for the Delay of Cataract Progression

Two patients have been implanted in the final cohort of the trial Final cohort is actively enrolling adult patients undergoing vitrectomy FORT WORTH, Texas, April 30, 2024 (GLOBE NEWSWIRE) --...
April 16, 2024 09:00 ET | Source: Nacuity Pharmaceuticals, Inc.

Nacuity Pharmaceuticals Expands Board of Directors with Appointment of Dr. Emmett Cunningham, Jr.

FORT WORTH, Texas, April 16, 2024 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing novel treatments for retinitis pigmentosa, cataract, and...
February 14, 2024 09:00 ET | Source: Nacuity Pharmaceuticals, Inc.

Nacuity Pharmaceuticals Announces Expansion of its Business Advisory Board with Appointment of Rare Disease Advocate Daniel Feller

FORT WORTH, Texas, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and other...
July 11, 2023 09:00 ET | Source: Nacuity Pharmaceuticals, Inc.

Nacuity Pharmaceuticals Advances Phase 1/2 Clinical Trial Evaluating NPI-002 Intravitreal Implant for the Delay of Cataract Progression

New clinical site added and early safety signals observed in trial for treatment of ocular disease caused by oxidative stress First cohort is expected to achieve full enrollment by third quarter...
May 31, 2023 09:00 ET | Source: Nacuity Pharmaceuticals, Inc.

Nacuity Pharmaceuticals Achieves Target Enrollment for Phase 1/2 Clinical Trial of NPI-001 for the Treatment of Retinitis Pigmentosa Associated with Usher Syndrome

Phase 1/2 SLO-RP trial completed target enrollment of 48 patients diagnosed with RP associated with USH Interim efficacy data anticipated by year end 2023 FORT WORTH, Texas, May 31, 2023 (GLOBE...
May 12, 2023 05:03 ET | Source: Research and Markets

Global Nonalcoholic Steatohepatitis (NASH) Diagnostics Market Outlook to 2035

Dublin, May 12, 2023 (GLOBE NEWSWIRE) -- The "Global Nonalcoholic Steatohepatitis (NASH) Diagnostics Market Outlook to 2035" report has been added to ResearchAndMarkets.com's offering. The market...
February 08, 2023 06:18 ET | Source: Research and Markets

Insights on the Cardiac Biomarkers Global Market to 2027

Dublin, Feb. 08, 2023 (GLOBE NEWSWIRE) -- The "Cardiac Biomarkers: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. This report summarizes the global...
October 24, 2022 05:13 ET | Source: Research and Markets

Cellular Health Screening Market Report 2022: Growth in the Adoption of Direct-To-Consumer Approach for the Availability of Kits Boosting Sector

Dublin, Oct. 24, 2022 (GLOBE NEWSWIRE) -- The "Cellular Health Screening Market Size, Share & Trends Analysis Report by Test Type (Single Test Panels, Multi-test Panels), by Sample Type (Blood,...
September 27, 2022 04:00 ET | Source: Conagen

Conagen unveils commercial production of high-purity non-GMO salidroside

Bedford, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Conagen announced the commercialization of its 99% high-purity salidroside made by bioconversion technology, an active ingredient from the herbal...

Next Page keyboard_arrow_right